HC Wainwright reissued their buy rating on shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) in a research note released on Wednesday, September 6th. They currently have a $7.00 price target on the biotechnology company’s stock.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a sell rating to a hold rating in a research note on Monday, May 15th. ValuEngine upgraded shares of Caladrius Biosciences from a strong sell rating to a sell rating in a research note on Friday, September 1st.
Shares of Caladrius Biosciences (NASDAQ CLBS) traded up 3.40% on Wednesday, reaching $3.95. The company had a trading volume of 32,820 shares. Caladrius Biosciences has a 52 week low of $2.65 and a 52 week high of $7.79. The stock’s 50 day moving average is $4.08 and its 200 day moving average is $4.55.
Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. On average, equities research analysts predict that Caladrius Biosciences will post ($2.42) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/09/13/caladrius-biosciences-clbs-buy-rating-reiterated-at-hc-wainwright.html.
Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Caladrius Biosciences by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after acquiring an additional 4,163 shares during the period. KCG Holdings Inc. lifted its stake in shares of Caladrius Biosciences by 74.6% in the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 15,501 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Caladrius Biosciences by 34.3% in the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 24,900 shares in the last quarter. Institutional investors own 6.84% of the company’s stock.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.